Teva Pharmaceutical Industries TEVA
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 99th percentile, 5-year average -6.6x
#2813 of 2996 stocks by PE (1 = cheapest)
Near the top of its 5-year range · 96th percentile, 5-year average 2.6x
#4638 of 5338 stocks by PB (1 = cheapest)
Near the top of its 5-year range · 97th percentile, 5-year average 1.2x
#3107 of 5161 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 5.74 | – | 2.63 | 96% (pricier than usual) | #4638 of 5338 (1 = cheapest) |
| PE | 91.23 | 25.53 | -6.64 | 99% (pricier than usual) | #2813 of 2996 (1 = cheapest) |
| PS | 2.66 | 2.68 | 1.18 | 97% (pricier than usual) | #3107 of 5161 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on TEVA.
Sign in to join the discussion.